Real-time quantitative PCR monitoring of minimal residual disease in CML after treatment
10.3760/cma.j.issn.1009-9921.2012.04.003
- VernacularTitle:实时荧光定量聚合酶链反应动态监测慢性粒细胞白血病治疗后微小残留病的研究
- Author:
Feifei HUO
;
Xin LIU
;
Zimin SUN
;
Weibo ZHU
;
Yujie SUN
;
Changcheng ZHENG
;
Jingsheng WU
;
Xiaoyan GAI
;
Yongsheng HAN
;
Huizhi YANG
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Minimal residual disease;
Real-time quantitative PCR
- From:
Journal of Leukemia & Lymphoma
2012;21(4):199-202
- CountryChina
- Language:Chinese
-
Abstract:
Objective To set up a real-time quantitative PCR approach for detection and quantification for bcr-abl transcripts in CML patients,and detect minimal residual disease (MRD) in CML by real-time quantitative PCR (RQ-PCR)and evaluate the significance of MRD detection.Methods The ber-abl.fusion gene expression in 80 patients with CML was analyzed by RQ-PCR. The patients were divided into three groups according to the different treatment, allogeneic hematopoietic stem cell transplantation group,imatinib group and hydroxyurea group. The change of bcr-abl fusion gene was monitored in CML patients before and after treatment.Results The average of RQ-PCR detection on newly diagnosed patients with CML in chronic phase was 6847.67 copies / 104 cells,the accelerated phase was 306 176.08 copies / 104 cells,and the average results were 944.33, 2.37, 0.29, 0 copies / 104 cells after allogeneic hematopoietic stem cell transplantation one month,6 months,12 months or 24 months respectively.The average of RQ-PCR detection after use imatinib mesylate 3 months was 3720.23 copies / 104 cells and not be detected after one year. The average was 7290.11 and 3143.24 copies / 104 cells after hydroxyurea treatment 0 and 9 months respectively.The difference in first two groups was not significant (t=1.74,P=0.17), but the difference between the third group and the first two groups was significant (t=3.74,P=0.01.t=2.97,P=0.02). The upregulation of bcr-abl transcript levels could be detected when disease progression. The transcripts level in accelerated phase was significantly higher than that in chronic phase. Conclusion RQ-PCR can be used to detect the MRD,monitor the treatment outcome,predict disease recurrence and give early intervention.
